[1]
J. R. S. dos Reis and L. G. de Andrade, “PHARMACEUTICAL FOLLOW-UP OF PATIENTS WITH THYROID GLAND DISORDERS”, REASE, vol. 7, no. 9, pp. 753–765, Sep. 2021, doi: 10.51891/rease.v7i9.2278.